Single User License
INR 133660
Site License
INR 267320
Corporate User License
INR 400980

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Melasma (Chlosma)-Pipeline Review, H2 2016

Melasma (Chlosma)-Pipeline Review, H2 2016

  • Products Id :- GMDHC8701IDB
  • |
  • Pages: 30
  • |
  • November 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Melasma (Chlosma)-Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melasma (Chlosma)-Pipeline Review, H2 2016, provides an overview of the Melasma (Chlosma) (Dermatology) pipeline landscape.

Melasma is a common skin problem. The condition causes dark, discolored patches on your skin. The dark patches in melasma could be triggered by several factors, including pregnancy, birth control pills, hormone replacement therapy (HRT and progesterone), family history of melasma, race, antiseizure medications, and other medications that make the skin more prone to pigmentation after exposure to ultraviolet (UV) light.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melasma (Chlosma)-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melasma (Chlosma) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 2 respectively.Melasma (Chlosma).

Melasma (Chlosma) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Melasma (Chlosma) (Dermatology).

The pipeline guide reviews pipeline therapeutics for Melasma (Chlosma) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Melasma (Chlosma) (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Melasma (Chlosma) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Melasma (Chlosma) (Dermatology)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Melasma (Chlosma) (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Melasma (Chlosma) (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Melasma (Chlosma) Overview 5

Therapeutics Development 6

Pipeline Products for Melasma (Chlosma)-Overview 6

Melasma (Chlosma)-Therapeutics under Development by Companies 7

Melasma (Chlosma)-Pipeline Products Glance 8

Clinical Stage Products 8

Early Stage Products 9

Melasma (Chlosma)-Products under Development by Companies 10

Melasma (Chlosma)-Companies Involved in Therapeutics Development 11

EpiPharm AG 11

Hyundai Pharmaceutical Co Ltd 12

RXi Pharmaceuticals Corp 13

Melasma (Chlosma)-Therapeutics Assessment 14

Assessment by Monotherapy Products 14

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

EPI-M13-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

NPH-29-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

tranexamic acid-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

TRY-26071-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

TRY-26077-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Melasma (Chlosma)-Dormant Projects 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Figures

Number of Products under Development for Melasma (Chlosma), H2 2016 6

Number of Products under Development by Companies, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Targets, H2 2016 15

Number of Products by Stage and Targets, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21

List of Tables

Number of Products under Development for Melasma (Chlosma), H2 2016 6

Number of Products under Development by Companies, H2 2016 7

Comparative Analysis by Clinical Stage Development, H2 2016 8

Comparative Analysis by Early Stage Development, H2 2016 9

Products under Development by Companies, H2 2016 10

Melasma (Chlosma)-Pipeline by EpiPharm AG, H2 2016 11

Melasma (Chlosma)-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2016 12

Melasma (Chlosma)-Pipeline by RXi Pharmaceuticals Corp, H2 2016 13

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Stage and Target, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Melasma (Chlosma)-Dormant Projects, H2 2016 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

EpiPharm AG, Hyundai Pharmaceutical Co Ltd, RXi Pharmaceuticals Corp

Melasma (Chlosma) Therapeutic Products under Development, Key Players in Melasma (Chlosma) Therapeutics, Melasma (Chlosma) Pipeline Overview, Melasma (Chlosma) Pipeline, Melasma (Chlosma) Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]